The specificity for murine CD38 makes our hcAbs unique tools to simultaneously assess the cytotoxicity mechanisms of CD38-specific hcAbs in vivo against tumor cells and their potential off-target effects on normal cells expressing CD38 in syngeneic mouse tumor models, i.e. in a fully immunocompetent background. Here, CD38 is linked to neoplasm.